Nav: Home

Pioneering research on mechanistic basis of disease in new journal Systems Medicine

March 13, 2018

New Rochelle, NY, March 13, 2018--The new peer-reviewed journal, Systems Medicine, has launched with a powerful mission to capture the leading research in the emerging field of medical systems biology. A fascinating Roundtable Discussion with key opinion leaders on the importance of systems medicine and interviews with thought leaders highlight the debut of Systems Medicine, a new open access journal from Mary Ann Liebert, Inc., publishers. The articles are available on the Systems Medicine website.

Co-Editors-in-Chief Harald H.H.W. Schmidt, MD, PhD, PharmD, Maastricht University, The Netherlands and Jan Baumbach, PhD, Technical University of Munich, Germany, discuss why the current approach to treating disease fails to drive successful new drug development in their Editorial entitled, "The End of Medicine as We Know It: Introduction to the New Journal, Systems Medicine." Modern omics technology is providing a new way to look at diseases and, combined with advanced molecular tools, a deeper understanding of systems biology, and big data, is enabling new mechanistic definitions of disease.

In an insightful Roundtable Discussion moderated by Dr. Schmidt, the expert panel examines the differences between systems medicine and current medicine and share their views on how systems medicine can help solve some of the problems plaguing classical medicine. Roundtable participants Jan Baumbach, Joseph Loscalzo, Alvar Agusti, Edwin Silverman, and Vasco Azevedo explore how an emphasis on molecular mechanistic biomarkers will help drive major innovations in new drug discovery and the development of novel preventive therapies based on research into the trajectories of healthy aging.

Newly published in Systems Medicine are interviews with two thought leaders on systems medicine: Charles Auffray, PhD, President, European Institute for Systems Biology & Medicine and Chair of the Executive Board, European Association of Systems Medicine, and Weiniu Gan, PhD, Program Director, Division of Lung Diseases, National Heart, Lung, and Blood Institute, U.S. National Institutes of Health.
-end-
About the Journal

Systems Medicine: Journal of Medical Systems Biology and Network Medicine is the premier open access, peer-reviewed journal focused on interdisciplinary approaches to exploiting the power of big data by applying systems biology and network medicine. Led by Co-Editors-in-Chief H.H.H.W. Schmidt, MD, PhD, PharmD, Maastricht University, and Jan Baumbach, PhD, Technical University of Munich, Germany, Systems Medicine yields major breakthroughs towards mechanism-based re-definitions of diseases for high-precision diagnostics and treatments. The Journal is collaborative partners with the European Cooperation in Science and Technology (COST), Italian Association for Systems Medicine and Healthcare (ASSIMSS), and European Association for Systems Medicine (EASYM). Complete tables of content can be viewed on the Systems Medicine website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Assay and Drug Development Technologies, Big Data, and OMICS: A Journal of Integrative Biology. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Mary Ann Liebert, Inc./Genetic Engineering News

Related Drug Discovery Articles:

Choosing a simpler path to drug discovery
Researchers from Kyoto University, MIT, and ETH Zurich have developed a compact drug discovery method using simple models and small data sets.
Drug discovery researchers awarded grant to refine malaria drug
A research team from the Virginia Tech Center for Drug Discovery has received a $431,126 two-year grant from the National Institutes of Health to make improved versions of a promising compound called MMV008138, or 8138 for short.
New computational tool may speed drug discovery
A new computational tool called fABMACS is helping scientists see beyond static images of proteins to more efficiently understand how these molecules function, which could ultimately speed up the drug discovery process.
Paving the road to drug discovery
When treated with an anti-cancer drug, ICRF-193, fission yeast produce an 'arched and snapped' phenotype that may be used to screen for other cancer drugs.
Open-source drug discovery a success
In what is being called the first-ever test of open-source drug-discovery, researchers from around the world have successfully identified compounds to pursue in treating and preventing parasite-borne illnesses such as malaria as well as cancer.
Celgene joins DNDi's 'Drug Discovery Booster'
The biopharmaceutical company Celgene has become the fifth company to join the 'Neglected Tropical Diseases Drug Discovery Booster' consortium, a new initiative to accelerate and cut the cost of early stage drug discovery for two of the world's most neglected diseases, leishmaniasis and Chagas disease.
Speeding up drug discovery to fight tuberculosis
Researchers at the Institute for Systems Biology and Center for Infectious Disease Research in Seattle have deciphered how the human pathogen Mycobacterium tuberculosis is able to tolerate the recently approved FDA drug bedaquiline.
Deep learning applied to drug discovery and repurposing
Scientists from Insilico Medicine in collaboration with Datalytic Solutions and Mind Research Network trained deep neural networks to predict the therapeutic use of large number of multiple drugs using gene expression data obtained from high-throughput experiments on human cell lines.
Breast cancer drug discovery offers hope of new treatments
A new drug discovery approach has yielded a potential therapy for breast cancer that may be more effective than existing medicines.
Current cancer drug discovery method flawed: Study
The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers report May 2 in Nature Methods.

Related Drug Discovery Reading:

Basic Principles of Drug Discovery and Development
by Benjamin Blass (Author)

Drugs: From Discovery to Approval
by Rick Ng (Author)

Peptide-based Drug Discovery: Challenges and New Therapeutics
by Ved Srivastava (Editor)

Drug Discovery and Development: Technology in Transition
by Raymond G Hill (Editor)

Successful Drug Discovery
by János Fischer (Editor), Wayne E. Childers (Editor)

Drug Discovery: A History
by Walter Sneader (Author)

Drug Discovery: Practices, Processes, and Perspectives
by Jie Jack Li (Editor), E. J. Corey (Editor)

Bioinformatics and Computational Biology in Drug Discovery and Development
by William T. Loging (Editor)

Hallelujah Moments: Tales of Drug Discovery
by Eugene H. Cordes (Author)

Textbook of Drug Design and Discovery
by Kristian Stromgaard (Editor), Povl Krogsgaard-Larsen (Editor), Ulf Madsen (Editor)

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Circular
We're told if the economy is growing, and if we keep producing, that's a good thing. But at what cost? This hour, TED speakers explore circular systems that regenerate and re-use what we already have. Guests include economist Kate Raworth, environmental activist Tristram Stuart, landscape architect Kate Orff, entrepreneur David Katz, and graphic designer Jessi Arrington.
Now Playing: Science for the People

#504 The Art of Logic
How can mathematics help us have better arguments? This week we spend the hour with "The Art of Logic in an Illogical World" author, mathematician Eugenia Cheng, as she makes her case that the logic of mathematics can combine with emotional resonance to allow us to have better debates and arguments. Along the way we learn a lot about rigorous logic using arguments you're probably having every day, while also learning a lot about our own underlying beliefs and assumptions.